DBVT DBV Technologies S.A.

7.63
+0.55  (+8%)
Previous Close 7.08
Open 7.17
Price To Book 4.36
Market Cap 551,305,589
Shares 72,254,992
Volume 768,361
Short Ratio
Av. Daily Volume 321,827
Stock charts supplied by TradingView

NewsSee all news

  1. DBV Technologies Announces Closing of Global Offering

    Montrouge, France, October 15, 2019 DBV Technologies Announces Closing of Global Offering DBV Technologies (the "Company") (GREY:DBVTF), a clinical-stage biopharmaceutical company, today announced the settlement and

  2. DBV Technologies Announces Full Exercise of Underwriters' Option to Purchase Additional Shares in Connection With its Global Offering of Ordinary Shares in the Form of American Depositary Shares (ADSs)

    Montrouge, France, October 10, 2019 DBV Technologies Announces Full Exercise of Underwriters' Option to Purchase Additional Shares in Connection With its Global Offering of Ordinary Shares in the Form of American

  3. DBV Technologies Announces Pricing of $125 million (€114 million) Global Offering of Ordinary Shares, Including in the Form of American Depositary Shares

    Montrouge, France, October 9, 2019 DBV Technologies Announces Pricing of $125 million (€114 million) Global Offering of Ordinary Shares, Including in the Form of American Depositary Shares DBV Technologies (the

  4. DBV Technologies Announces the Launch of a Proposed Global Offering of Ordinary Shares, Which May Be in the Form of American Depositary Shares, and Reports September 30, 2019 Cash Position

    Montrouge, France, October 8, 2019 DBV Technologies Announces the Launch of a Proposed Global Offering of Ordinary Shares, Which May Be in the Form of American Depositary Shares, and Reports September 30, 2019 Cash

  5. DBV Technologies Announces FDA Acceptance of BLA filing for Viaskin Peanut for the Treatment of Peanut Allergy

    Montrouge, France, October 4, 2019DBV Technologies Announces FDA Acceptance of BLA filing for Viaskin Peanut for the Treatment of Peanut Allergy If approved, Viaskin Peanut would be the first and only epicutaneous

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1/2 data released February 2018.
Viaskin Milk
Cow’s milk protein allergy (CMPA)
PDUFA date August 5, 2020.
Viaskin Peanut
Peanut allergy
Phase 3 (Part B) initiation announced October 26, 2018.
Viaskin Peanut (EPITOPE)
Peanut allergy

Latest News

  1. DBV Technologies Announces Closing of Global Offering

    Montrouge, France, October 15, 2019 DBV Technologies Announces Closing of Global Offering DBV Technologies (the "Company") (GREY:DBVTF), a clinical-stage biopharmaceutical company, today announced the settlement and

  2. DBV Technologies Announces Full Exercise of Underwriters' Option to Purchase Additional Shares in Connection With its Global Offering of Ordinary Shares in the Form of American Depositary Shares (ADSs)

    Montrouge, France, October 10, 2019 DBV Technologies Announces Full Exercise of Underwriters' Option to Purchase Additional Shares in Connection With its Global Offering of Ordinary Shares in the Form of American

  3. DBV Technologies Announces Pricing of $125 million (€114 million) Global Offering of Ordinary Shares, Including in the Form of American Depositary Shares

    Montrouge, France, October 9, 2019 DBV Technologies Announces Pricing of $125 million (€114 million) Global Offering of Ordinary Shares, Including in the Form of American Depositary Shares DBV Technologies (the

  4. DBV Technologies Announces the Launch of a Proposed Global Offering of Ordinary Shares, Which May Be in the Form of American Depositary Shares, and Reports September 30, 2019 Cash Position

    Montrouge, France, October 8, 2019 DBV Technologies Announces the Launch of a Proposed Global Offering of Ordinary Shares, Which May Be in the Form of American Depositary Shares, and Reports September 30, 2019 Cash

  5. DBV Technologies Announces FDA Acceptance of BLA filing for Viaskin Peanut for the Treatment of Peanut Allergy

    Montrouge, France, October 4, 2019DBV Technologies Announces FDA Acceptance of BLA filing for Viaskin Peanut for the Treatment of Peanut Allergy If approved, Viaskin Peanut would be the first and only epicutaneous

  6. Monthly information regarding the total number of voting rights and total number of shares of the Company

                                                                                                                                                                                                                                

  7. Monthly information regarding the total number of voting rights and total number of shares of the Company